Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACHIEVE phase 2 study of HM15136 in congenital hyperinsulinism
MOH_2022-11-06_012160Phase 2Not yet recruiting
- Sponsor
- Hanmi Pharmaceutical
- Start
- Jul 2022
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label trial of efpegerglucagon in congenital hyperinsulinism (HI) (4 cohorts), sponsored by Hanmi Pharmaceutical. Primary endpoints: Safety and tolerability of HM15136, Pharmacokinetics of HM15136 and 1 more. Planned start Jul 2022; status: not yet recruiting.
02
Drugs
efpegerglucagon
03
Conditions
congenital hyperinsulinism (HI)
Beyond the preview
Go deeper on MOH_2022-11-06_012160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-11-06_012160.